PMID- 22525474
OWN - NLM
STAT- MEDLINE
DCOM- 20130402
LR  - 20181201
IS  - 0386-300X (Print)
IS  - 0386-300X (Linking)
VI  - 66
IP  - 2
DP  - 2012
TI  - Long-term effects of cabergoline and levodopa in Japanese patients with early 
      Parkinson's disease: a 5-year prospective study.
PG  - 163-70
AB  - Several international studies have suggested that treatment of early Parkinson's 
      disease (PD) with a dopamine agonist instead of levodopa delays the occurrence of 
      motor complications. This 5-year prospective, open, multicenter randomized study 
      aimed to compare the effects of cabergoline on the onset of motor complications 
      with those of levodopa in Japanese patients with early PD. Patients who had never 
      been treated with dopamine agonists or levodopa were enrolled in this study. Four 
      of 45 patients in the cabergoline group and 11 of 46 patients in the levodopa 
      group developed motor complications. The estimated cumulative incidence of motor 
      complications in the cabergoline and levodopa groups was 17% and 34% (hazard 
      ratio, 0.57;95% confidence interval, 0.18-1.81; p = 0.347). Thirty-five adverse 
      events (AEs) were reported in 24 patients in the cabergoline group, while 16 AEs 
      were reported in 13 patients in the levodopa group. Patients in the cabergoline 
      group showed fewer motor complications than did those in the levodopa group, 
      although the difference was not statistically significant. However, the hazard 
      ratio found in this study was similar to those in previous reports.
FAU - Utsumi, Hiroya
AU  - Utsumi H
AD  - Department of Neurology, Tokyo Medical University Hospital, Shinjuku-ku, Japan. 
      utsumi-h@tokyo-med.ac.jp
CN  - Cabergoline as the Starting Treatment and its Long-term Effects (CASTLE) Study 
      Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Acta Med Okayama
JT  - Acta medica Okayama
JID - 0417611
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Dopamine Agonists)
RN  - 0 (Ergolines)
RN  - 46627O600J (Levodopa)
RN  - LL60K9J05T (Cabergoline)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antiparkinson Agents/adverse effects/*therapeutic use
MH  - Cabergoline
MH  - Dopamine Agonists/adverse effects/*therapeutic use
MH  - Ergolines/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Japan
MH  - Levodopa/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Parkinson Disease/*drug therapy
MH  - Prospective Studies
MH  - Time
MH  - Treatment Outcome
FIR - Shimizu, Yuko
IR  - Shimizu Y
FIR - Murakami, Tatsufumi
IR  - Murakami T
FIR - Ohsawa, Yutaka
IR  - Ohsawa Y
FIR - Iizuka, Takahiro
IR  - Iizuka T
FIR - Takahashi, Kazushi
IR  - Takahashi K
FIR - Nogawa, Shigeru
IR  - Nogawa S
FIR - Takeda, Hidetada
IR  - Takeda H
FIR - Amano, Takahiro
IR  - Amano T
FIR - Yamamoto, Toshimasa
IR  - Yamamoto T
FIR - Shimazu, Kunio
IR  - Shimazu K
FIR - Morita, Mitsuya
IR  - Morita M
FIR - Fujimoto, Ken-ichi
IR  - Fujimoto K
FIR - Murakami, Hidetomo
IR  - Murakami H
FIR - Hasegawa, Yukihiro
IR  - Hasegawa Y
FIR - Yoshii, Fumihito
IR  - Yoshii F
FIR - Takahashi, Hirohide
IR  - Takahashi H
FIR - Terashi, Hiroo
IR  - Terashi H
FIR - Nagashima, Takahide
IR  - Nagashima T
FIR - Sakurai, Kunihiko
IR  - Sakurai K
FIR - Kaji, Yoshiaki
IR  - Kaji Y
FIR - Kawakami, Toshiyuki
IR  - Kawakami T
FIR - Kokubun, Norito
IR  - Kokubun N
FIR - Daimon, Yasutoshi
IR  - Daimon Y
FIR - Kubo, Hitoshi
IR  - Kubo H
FIR - Ishihara, Tetsuya
IR  - Ishihara T
FIR - Nagayama, Hiroshi
IR  - Nagayama H
FIR - Hamamoto, Makoto
IR  - Hamamoto M
FIR - Kamei, Satoshi
IR  - Kamei S
FIR - Suzuki, Yutaka
IR  - Suzuki Y
FIR - Sonno, Masahiro
IR  - Sonno M
EDAT- 2012/04/25 06:00
MHDA- 2013/04/03 06:00
CRDT- 2012/04/25 06:00
PHST- 2012/04/25 06:00 [entrez]
PHST- 2012/04/25 06:00 [pubmed]
PHST- 2013/04/03 06:00 [medline]
AID - 10.18926/AMO/48266 [doi]
PST - ppublish
SO  - Acta Med Okayama. 2012;66(2):163-70. doi: 10.18926/AMO/48266.